Cheryl Kuai holds both a PhD and the CFA charter and has cofounded a biotechnology company, combining scientific depth, financial training, and firsthand startup experience in how she looks at biotech investments—she focuses on companies that pair strong AI models with real biological expertise and proprietary data, and she has spoken about how validated lab results, not just computer predictions, are what actually set strong biotech companies apart. At Sixty Degree Capital, she has backed and publicly discussed companies advancing protein degrader technology, such as Monte Rosa and GlycoEra, as well as detailed oncology science like Nested Therapeutics' melanoma program, and she stays closely engaged with the companies she backs, marking milestones such as Bionyra's $165 million Series A and Parabilis' Nasdaq listing.